
Protagonist Therapeutics (PTGX) Stock Forecast & Price Target
Protagonist Therapeutics (PTGX) Analyst Ratings
Bulls say
Protagonist Therapeutics Inc has demonstrated promising clinical results for its leading candidate, icotrokinra, showcasing notable improvements in clinical response rates and endoscopic outcomes, which may drive significant growth in the inflammatory diseases market. The company's robust pipeline, underpinned by innovative peptide-based therapeutics and a strong business development track record, positions it favorably for momentum through anticipated key catalysts in 2025. Additionally, the submission of a New Drug Application for icotrokinra in psoriasis, coupled with data highlighting its efficacy in difficult-to-treat areas, further enhances the company's growth prospects as it prepares for market entry.
Bears say
Protagonist Therapeutics Inc faces significant challenges related to its pipeline candidates, particularly icotrokinra, as it is subject to inherent industry risks such as unexpected safety concerns, potential strategic partnership withdrawals, and increased regulatory and competitive pressures. Additionally, the company must navigate a complex commercial landscape, which includes pricing reform and the potential for cash needs that could lead to dilution of current shareholder value. Such uncertainties in clinical efficacy, marketability, and financial stability contribute to a negative outlook for Protagonist Therapeutics's stock performance.
This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Protagonist Therapeutics (PTGX) Analyst Forecast & Price Prediction
Start investing in Protagonist Therapeutics (PTGX)
Order type
Buy in
Order amount
Est. shares
0 shares